Reuters: Regulatory News: FDA postpones panel for Glaxo's COPD drug as snowstorm advances

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

FDA postpones panel for Glaxo's COPD drug as snowstorm advances Mar 5th 2013, 22:39 March 5 | Tue Mar 5, 2013 5:39pm EST March 5 (Reuters) - The U.S. Food and Drug Administration said on Tuesday it has postponed a meeting of outside advisers scheduled for March 7 to review a drug developed by GlaxoSmithKline Plc and Theravance Inc for chronic obstructive pulmonary disease (COPD). The agency did not officially give a reason for the postponement but it comes as a major snowstorm bears down on the Northeastern United States, including Washington D.C., where the panelists were due to meet. The agency said it would post briefing materials related to the drug, to be called Breo if approved in the United States, no later than two days before the next meeting, once announced.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions